Astromech Secures $20 Million to Pioneer Predictive AI Biology, Valued at $3.8 Billion
August 24, 2026, 9:37 am
Location: United States
Employees: 51-200
Founded date: 2021
Total raised: $805M
Location: United States, Illinois, Chicago
Employees: 11-50
Founded date: 1986
Astromech, a cutting-edge computational biology firm, recently secured $20 million in funding. This capital injection propels its mission: to forecast biological evolution using advanced AI. The company aims to predict how living systems change. It identifies potential systemic breakdowns before they occur. This round, led by Bob Nelsen, brings Astromech's valuation to $3.8 billion. The company, a Colossal Biosciences spin-out, applies its models to cellular longevity. It maps cancer resistance genes. Its technology forecasts pathogen evolution. It anticipates disease progression. It flags climate-stressed ecosystems. This marks a paradigm shift from reactive to predictive biology.
Astromech, a leader in AI biology, closed a $20 million funding round. The investment boosts its innovative platform. This platform predicts evolutionary changes in living systems. Bob Nelsen, co-founder of ARCH Venture Partners, led the round. PEAK6, NeoGenesis Capital, Builders VC, and CAZ Investments also participated. This financing elevates Astromech's valuation to $3.8 billion. The total capital raised by the company now stands at $60 million.
Biology has long operated reactively. Diseases emerge, then research follows. Species vanish, then extinction studies begin. Astromech challenges this reactive model. The company aims to anticipate biological shifts. It seeks to identify vulnerabilities proactively. This predictive approach promises a revolution in life sciences.
Astromech calls its method "evolutionary forecasting." It draws an analogy to weather prediction. Meteorologists combine current data with historical patterns. They forecast storms. Astromech applies this logic to biology. It integrates current genomic data. It uses deep evolutionary history. This combination predicts biological change.
Ben Lamm leads Astromech as CEO. He co-founded the company with Harvard geneticist George Church. This duo also launched Colossal Biosciences in 2021. Colossal focuses on de-extinction projects. It aims to revive species like the woolly mammoth. Astromech takes a different path. It deciphers existing DNA information. It uncovers hidden evolutionary records.
The company's core advantage lies in its data. Astromech accesses Colossal's extensive genome bank. This includes both extinct and living species. It also leverages other proprietary datasets. This gives Astromech functional genomic information. It spans thousands of lineages. This goes beyond typical human and lab mouse data.
Genetic variation is critical for complex traits. Much of this variation resides in regulatory regions of DNA. These regions control gene activation. Understanding them requires diverse species data. A simple sequence is not enough. Astromech gathers this multi-species functional data. Its AI reconstruction methods are efficient. They enable genome-wide analysis at scale.
Astromech trains AI models. These models trace trait evolution. They decode what changed and when. They reveal the resulting tradeoffs. Every genome holds this intricate record. Astromech builds the AI to read it. This unlocks unprecedented biological insight.
The company showcased its platform's power. It mapped 46 genes linked to longevity. It charted these genes across a time-calibrated tree of life. Researchers can now observe how traits evolved. Cancer resistance, cellular repair, and aging processes are illuminated. This spans millions of years. It moves beyond single-gene, single-species studies. Insights come from species like bowhead whales, bats, and elephants. These creatures possess unique defense mechanisms against cellular aging.
The new capital funds crucial scaling efforts. Astromech will expand its specialized teams. This includes machine learning and computational biology experts. It will acquire more multi-species genomic datasets. The company will also enhance its computing infrastructure. This heavy compute power is vital for scaling foundational AI models.
Astromech is transitioning to pilot projects. It plans forecasting initiatives with partners. These collaborations will span health and biosecurity sectors. The goal is to test the AI's predictive capabilities. Can AI anticipate genetic bottlenecks? Can it foresee environmental responses? Can it forecast pathogen evolution? Can it predict disease progression? These are critical questions for global well-being.
The technology offers vast applications. It can anticipate zoonotic pathogens. These diseases transfer from animals to humans. It can forecast oncology mutation paths. This informs cancer treatment strategies. It can flag climate-stressed ecosystems. Early detection allows for intervention. This proactive approach could save lives and ecosystems.
Astromech's work represents a fundamental shift. It moves biology from description to prediction. Its advanced AI models analyze historical genomic data. They forecast biological outcomes before they manifest. This predictive forecasting engine for living systems holds immense promise. It transforms how humanity understands and interacts with life itself. The future of biology is becoming predictable.
Astromech, a leader in AI biology, closed a $20 million funding round. The investment boosts its innovative platform. This platform predicts evolutionary changes in living systems. Bob Nelsen, co-founder of ARCH Venture Partners, led the round. PEAK6, NeoGenesis Capital, Builders VC, and CAZ Investments also participated. This financing elevates Astromech's valuation to $3.8 billion. The total capital raised by the company now stands at $60 million.
Biology has long operated reactively. Diseases emerge, then research follows. Species vanish, then extinction studies begin. Astromech challenges this reactive model. The company aims to anticipate biological shifts. It seeks to identify vulnerabilities proactively. This predictive approach promises a revolution in life sciences.
Astromech calls its method "evolutionary forecasting." It draws an analogy to weather prediction. Meteorologists combine current data with historical patterns. They forecast storms. Astromech applies this logic to biology. It integrates current genomic data. It uses deep evolutionary history. This combination predicts biological change.
Ben Lamm leads Astromech as CEO. He co-founded the company with Harvard geneticist George Church. This duo also launched Colossal Biosciences in 2021. Colossal focuses on de-extinction projects. It aims to revive species like the woolly mammoth. Astromech takes a different path. It deciphers existing DNA information. It uncovers hidden evolutionary records.
The company's core advantage lies in its data. Astromech accesses Colossal's extensive genome bank. This includes both extinct and living species. It also leverages other proprietary datasets. This gives Astromech functional genomic information. It spans thousands of lineages. This goes beyond typical human and lab mouse data.
Genetic variation is critical for complex traits. Much of this variation resides in regulatory regions of DNA. These regions control gene activation. Understanding them requires diverse species data. A simple sequence is not enough. Astromech gathers this multi-species functional data. Its AI reconstruction methods are efficient. They enable genome-wide analysis at scale.
Astromech trains AI models. These models trace trait evolution. They decode what changed and when. They reveal the resulting tradeoffs. Every genome holds this intricate record. Astromech builds the AI to read it. This unlocks unprecedented biological insight.
The company showcased its platform's power. It mapped 46 genes linked to longevity. It charted these genes across a time-calibrated tree of life. Researchers can now observe how traits evolved. Cancer resistance, cellular repair, and aging processes are illuminated. This spans millions of years. It moves beyond single-gene, single-species studies. Insights come from species like bowhead whales, bats, and elephants. These creatures possess unique defense mechanisms against cellular aging.
The new capital funds crucial scaling efforts. Astromech will expand its specialized teams. This includes machine learning and computational biology experts. It will acquire more multi-species genomic datasets. The company will also enhance its computing infrastructure. This heavy compute power is vital for scaling foundational AI models.
Astromech is transitioning to pilot projects. It plans forecasting initiatives with partners. These collaborations will span health and biosecurity sectors. The goal is to test the AI's predictive capabilities. Can AI anticipate genetic bottlenecks? Can it foresee environmental responses? Can it forecast pathogen evolution? Can it predict disease progression? These are critical questions for global well-being.
The technology offers vast applications. It can anticipate zoonotic pathogens. These diseases transfer from animals to humans. It can forecast oncology mutation paths. This informs cancer treatment strategies. It can flag climate-stressed ecosystems. Early detection allows for intervention. This proactive approach could save lives and ecosystems.
Astromech's work represents a fundamental shift. It moves biology from description to prediction. Its advanced AI models analyze historical genomic data. They forecast biological outcomes before they manifest. This predictive forecasting engine for living systems holds immense promise. It transforms how humanity understands and interacts with life itself. The future of biology is becoming predictable.